Which of the following is a serious adverse effect seen with zolendronate?
Wait, the user provided the correct answer as "Osteonecrosis of the jaw (ONJ)" but the options A-D are missing. The correct answer line in the example shows that the correct answer is labeled with a letter and the text. So, in the explanation, I need to structure it accordingly.
Core Concept: Zolendronate is a bisphosphonate that inhibits osteoclast activity by binding to hydroxyapatite in bone. Long-term use can lead to serious adverse effects, particularly in patients with cancer receiving high-dose infusions for bone metastases.
Why the Correct Answer is Right: Osteonecrosis of the jaw (ONJ) is a rare but serious complication. It's thought to occur due to impaired bone remodeling, leading to poor healing after dental procedures. The mechanism involves osteoclast suppression, leading to accumulation of microdamage and reduced vascular supply in the jawbone.
Wrong Options: Let's consider other possible adverse effects. Hypocalcemia is a risk, especially in patients with renal impairment. Myalgias and flu-like symptoms are common with bisphosphonates but not considered serious. Atypical femoral fractures are another serious effect, but the question is about the most common or classic one. So, if the options include hypocalcemia, myalgia, or atypical fractures, those would be incorrect here.
Clinical Pearl: Remember that ONJ is more common with intravenous bisphosphonates, especially in cancer patients. Dental evaluation before starting therapy is crucial.
Now, structuring the explanation with all the required sections. Need to make sure each part is concise and fits within the character limit. Also, use bold for key terms and avoid markdown except for bold. Check the example provided to match the structure and language.
**Core Concept**
Zolendronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Prolonged use, especially intravenously, is associated with **osteonecrosis of the jaw (ONJ)**, a serious adverse effect linked to impaired bone remodeling and poor healing in the maxillofacial region.
**Why the Correct Answer is Right**
**Osteonecrosis of the jaw (ONJ)** occurs in 1-10% of patients on high-dose intravenous bisphosphonates (e.g., for bone metastases). The mechanism involves osteoclast suppression, leading to microdamage accumulation, reduced vascular supply, and subsequent avascular necrosis. Risk factors include dental procedures, poor oral hygiene, and prolonged therapy.